Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
17.56
-0.39 (-2.17%)
At close: Dec 5, 2025, 4:00 PM EST
17.22
-0.34 (-1.94%)
After-hours: Dec 5, 2025, 6:20 PM EST
Avalo Therapeutics Employees
Avalo Therapeutics had 23 employees as of December 31, 2024. The number of employees increased by 4 or 21.05% compared to the previous year.
Employees
23
Change (1Y)
4
Growth (1Y)
21.05%
Revenue / Employee
$8,348
Profits / Employee
-$4,334,826
Market Cap
318.43M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AVTX News
- 18 days ago - Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 4 weeks ago - Avalo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa - GlobeNewsWire
- 2 months ago - Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources - GlobeNewsWire
- 2 months ago - Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors - GlobeNewsWire
- 3 months ago - Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009's LOTUS Results - Seeking Alpha
- 4 months ago - Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire